March 12, 2018 / 11:46 AM / 5 months ago

BRIEF-Sarepta Therapeutics Announces Plan To Submit A New Drug Application For Accelerated Approval Of Golodirsen

March 12 (Reuters) - Sarepta Therapeutics Inc:

* SAREPTA THERAPEUTICS ANNOUNCES PLAN TO SUBMIT A NEW DRUG APPLICATION (NDA) FOR ACCELERATED APPROVAL OF GOLODIRSEN (SRP-4053) IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) AMENABLE TO SKIPPING EXON 53

* SAREPTA THERAPEUTICS INC - INTENDS TO COMPLETE A ROLLING SUBMISSION OF A GOLODIRSEN NDA BY YEAR-END 2018

* SAREPTA THERAPEUTICS INC - MET WITH FDA DIVISION OF NEUROLOGY PRODUCTS IN FEBRUARY TO OBTAIN GUIDANCE ON REGULATORY PATHWAY FOR GOLODIRSEN Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below